Otsuka Corporation (TYO:4768)
Japan
· Delayed Price · Currency is JPY | Market Cap | 1.18T |
| Revenue (ttm) | 1.23T |
| Net Income (ttm) | 60.68B |
| Shares Out | 379.20M |
| EPS (ttm) | 160.02 |
| PE Ratio | 19.45 |
| Forward PE | 19.81 |
| Dividend | 80.00 (2.54%) |
| Ex-Dividend Date | Dec 29, 2025 |
| Volume | 739,100 |
| Average Volume | 1,111,530 |
| Open | 3,132.00 |
| Previous Close | 3,151.00 |
| Day's Range | 3,101.00 - 3,138.00 |
| 52-Week Range | 2,815.00 - 3,789.00 |
| Beta | 0.20 |
| RSI | 59.75 |
| Earnings Date | Aug 1, 2025 |
About Otsuka
Otsuka Corporation, together with its subsidiaries, operates as an information technology (IT) platformer in Japan. It operates through System Integration Business, and Service and Support Business segments. The System Integration Business segment offers management systems and collaborative software, such as ERP packages and groupware to cover a range of specialized fields, including CAD and web technologies; and software, hardware, intranet, and security products for the construction and expansion of computer networks, as well as intermediary ... [Read more]
Financial Performance
In 2024, Otsuka's revenue was 1.11 trillion, an increase of 13.33% compared to the previous year's 977.37 billion. Earnings were 53.48 billion, an increase of 12.71%.
Financial StatementsNews
Otsuka’s PTSD therapy draws efficacy concerns at FDA ahead of AdCom meeting
SeaStar Medical's QUELIMMUNE Wins Prestigious Award From The National Kidney Foundation, Former Winners Include Names Like Janssen, Merck and Otsuka
When it comes to unmet needs in the nephrology space, acute kidney injury remains a significant concern. That's particularly true regarding pediatric AKI – each year, about 4,000 children with AKI req...
Vera plunges as Otsuka outperforms with IgA nephropathy therapy
Otsuka Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)
The FDA target action date (PDUFA date) is set for November 28, 2025 If approved, sibeprenlimab would offer patients a convenient single-dose prefilled syringe for subcutaneous injection every four we...
Arbitrum DAO mulls winding down unsustainable Web3 gaming fund
Members of Arbitrum’s decentralized autonomous organization (DAO) are discussing a potential clawback of funds allocated to build a gaming ecosystem on the network, citing a lack of progress and trans...
Vera Therapeutics: Does The Earlier Otsuka Launch Harm Its Prospects Much?
Vera plunges as Otsuka updates on rival therapy
Otsuka submits NDA in Japan for the treatment of hypercholesterolemia
Esperion's partner Otsuka submits New Drug Application for bempedoic acid in Japan for hypercholesterolemia treatment.Expansion of market potential.
ICU Medical, Otsuka team up to boost US IV solutions production
Otsuka Is Said to Weigh Sale of Stake in Medical Device Maker MicroPort Scientific
Otsuka Holdings Co. is considering options for its holding in Hong Kong-listed MicroPort Scientific Corp., including selling its stake in the medical device maker, according to people familiar with th...
Citi maintains ‘Sell’ rating on Lupin, sets target at Rs 1,700
Citi has reiterated its “Sell” recommendation for Lupin, with a target price of Rs 1,700 per share. This comes in light of recent developments regarding Lupin’s generic version of Jynarque. Key points...